phlove 25
phlove 25
Is the CFP bracket fair? Here are some tweaks that would have changed things
Onex Corporation Announces Exemptive Relief in Substantial Issuer Bid
China may be playing its biggest economic card yet. According to sources cited by Reuters this week, Chinese policymakers are considering allowing the yuan to weaken significantly in 2025 to counter the economic impact of a potential 60% tariff on Chinese imports by the United States. This move would mark a major shift in Beijing's currency strategy as the country grapples with mounting economic pressures. But will it actually work? A Weaker Yuan: A Double-Edged Sword? President-elect Donald Trump 's proposed tariffs—10% on all imports and a massive 60% on Chinese goods—have prompted Beijing to consider devaluation as a buffer. A weaker yuan could theoretically make Chinese exports cheaper and offset the sting of U.S. tariffs. Yet, Beijing is walking a tightrope. According to Lynn Song, an analyst at ING, the People's Bank of China is expected to “mount a strong defense” of the yuan. The central bank is acutely aware that if the renminbi falls too sharply, it could trigger even harsher retaliatory measures from Washington. In response to the rumors, Financial News, a PBOC-affiliated publication, insisted the yuan remains on solid footing and predicted the currency could stabilize and strengthen by the end of the year. China's Real Problem: A Balance Sheet Recession Tariffs aren't China's only problem. The country is facing a multi-front economic battle, with a housing market that's imploding, a weak stock market, and slowing consumer activity. "The gentle de-leveraging of the housing market that policymakers had in mind turned into a vicious balance sheet recession," said Alfonso Peccatiello , chief investing officer at Palinuro Capital and founder of The Macro Compass. "Trillions in wealth tied to real estate have been wiped out since 2021." A balance sheet recession is brutal. In this scenario, consumers and businesses prioritize repairing their finances over spending or investing, rendering typical monetary policy tools like interest rate cuts or currency devaluation largely ineffective. This type of economic slowdown recalls the eurozone debt crisis of 2011-2012, when fiscal austerity measures rendered monetary policy largely ineffective in stimulating the real economy. Beijing's Response So Far China’s policy response thus far has lacked courage, to say the least. Authorities have floated mentions of small-scale fiscal stimulus, though these efforts lack the size and scope to move the needle. The government has also set up mechanisms to deter investors from shorting Chinese stocks, aiming to stabilize markets. Additionally, the central bank has slashed interest rates aggressively to boost liquidity. Despite these interventions, the economy has failed to gain meaningful traction, leaving analysts and investors skeptical about Beijing's strategy. The iShares MSCI China ETF MCHI – a key benchmark tracking Chinese equities – continues to remain nearly 50% below its record highs achieved in February 2021. Why a Weaker Yuan Won't Fix This The idea of weakening the yuan might sound like a magic bullet, but economists aren't sold on the effectiveness of this strategy. "In a balance sheet recession, consumers and corporates can’t be encouraged to spend more by cutting interest rates or weakening the currency," Peccatiello said. "They are bleeding, and they see their net worth declining due to continued weakness in the property market." Simply put, a weaker currency won’t rebuild shattered wealth or restore confidence among Chinese households and businesses. What's The Real Solution? For Peccatiello, the solution for China may lie in implementing a large, targeted fiscal stimulus. Rather than broad, unspecific measures, some suggest that the government could consider directing significant spending toward struggling corporations and consumers. The question remains: Will Beijing take substantial steps toward fiscal stimulus? Read now: Defense Stocks Face Headwinds As Trump’s DOGE Targets Spending Cuts: Goldman Sachs Downgrades General Dynamics Photo: Shutterstock © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ange Postecoglou described a Tottenham forward Timo Werner's performance against Rangers as 'not acceptable' in a stinging spray. Postecoglou's side drew 1-1 with Rangers in the Europa League, meaning the Scottish club are still yet to beat an English Premier League club in European competition since November 1992. It was Rangers who struck first in the 47th minute as Hamza Igamane lashed home an inviting cross by James Tavernier from the right. However, Tottenham's Dejan Kulusevksi ensured the visitors would leave Ibrox with a point when he scored 15 minutes before the end. Kulusevski began the contest on the bench but was thrown on at the start of the second half. The Swede came on in place of Timo Werner , who was largely ineffectual for the opening 45 minutes and gave Postecoglou little reason to keep him on. Postecoglou didn't mince his words on Werner's performance and he certainly let the German know it. "He wasn't playing anywhere near the level he should," Postecoglou said in his post-match press conference. "When you’ve got 18-year-olds it’s not acceptable to me. I said that to Timo. He’s a senior international, he’s a German international. "In the moment we’re in right now, it’s not like we’ve got many options. I need everyone to at least be going out there trying to give the best of themselves. "His performance in the first half wasn’t acceptable." Postecoglou added: "We need everybody including him to be contributing, because we don’t have the depth to leave people out if they’re performing poorly. "We need them to play their part. Especially the senior guys. When I’m asking younger guys to do massive jobs. "I expect a level of performance from some of the senior guys and today wasn’t that." Werner's blank against Rangers meant his goal tally this season remained at just one from 19 appearances across all competitions. It was far from a perfect performance from Tottenham, whose defensive issues were exposed once more. In fact, Igamane's strike ensured Postecoglou's side had kept just one clean sheet from their last 11 games. Rangers also finished the contest with more shots and shots on target than their Premier League counterparts despite having 41 per cent possession. The display, especially defensively, left former Tottenham player Jamie O'Hara feeling like he's 'had enough'. "My patience is wearing thin," O'Hara said on The Sports Bar. "Patience is wearing thin. Ange Postecoglou, mate. I've had enough. "You know, we go on and like, oh yeah, the football's great. Is it? Is it great? “I'm not watching Barcelona. I'm just watching a good team, you know, in moments, have some decent spells, but you know, every team plays good football. “It's not like I'm watching Barcelona play, but can't defend, but when we've got the ball, it's just, you know, it's brilliant to watch. All I'm watching is a Tottenham team that I've watched a million times before. Boring. “There's nothing special.” Postecoglou will hope Tottenham's winless run doesn't stretch to a sixth game on Sunday as they travel to lowly Southampton .
NoneFitness set to determine Tottenham star’s future in North London; January exit possibleRICHMOND, Va.--(BUSINESS WIRE)--Dec 12, 2024-- The Board of Directors of NewMarket Corporation (NYSE: NEU) (the “Company”) approved a new share repurchase program authorizing management to repurchase up to $500 million of the Company’s outstanding common stock through December 31, 2027, as market conditions warrant and covenants under the Company’s existing debt agreements permit. The new repurchase program will replace the Company’s existing $500 million repurchase program approved by the Board of Directors in October 2021, which will expire on December 31, 2024. Under the new program, the Company may conduct share repurchases in the open market, in privately negotiated transactions, through block trades or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The new program does not require the Company to acquire any specific number of shares and may be terminated or suspended at any time. NewMarket Corporation is a holding company operating through its subsidiaries Afton Chemical Corporation (Afton), Ethyl Corporation (Ethyl), and American Pacific Corporation (AMPAC). The Afton and Ethyl companies develop, manufacture, blend, and deliver chemical additives that enhance the performance of petroleum products. AMPAC is a manufacturer of specialty materials primarily used in solid rocket motors for the aerospace and defense industries. The NewMarket family of companies has a long-term commitment to its people, to safety, to providing innovative solutions for its customers, and to making the world a better place. Some of the information contained in this press release constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although NewMarket’s management believes its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurance that actual results will not differ materially from expectations. Factors that could cause actual results to differ materially from expectations include, but are not limited to, the availability of raw materials and distribution systems; disruptions at production facilities, including single-sourced facilities; hazards common to chemical businesses; the ability to respond effectively to technological changes in our industries; failure to protect our intellectual property rights; sudden, sharp, or prolonged raw material price increases; competition from other manufacturers; current and future governmental regulations; the loss of significant customers; termination or changes to contracts with contractors and subcontractors of the U.S. government or directly with the U.S. government; failure to attract and retain a highly-qualified workforce; an information technology system failure or security breach; the occurrence or threat of extraordinary events, including natural disasters, terrorist attacks, wars and health-related epidemics; risks related to operating outside of the United States; political, economic, and regulatory factors concerning our products; the impact of substantial indebtedness on our operational and financial flexibility; the impact of fluctuations in foreign exchange rates; resolution of environmental liabilities or legal proceedings; limitation of our insurance coverage; our inability to realize expected benefits from investment in our infrastructure or from acquisitions, or our inability to successfully integrate acquisitions into our business; the underperformance of our pension assets resulting in additional cash contributions to our pension plans; and other factors detailed from time to time in the reports that NewMarket files with the Securities and Exchange Commission, including the risk factors in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023 and Part II, Item 1A. “Risk Factors” of our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, which are available to shareholders at www.newmarket.com . You should keep in mind that any forward-looking statement made by NewMarket in the foregoing discussion speaks only as of the date on which such forward-looking statement is made. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect the Company. We have no duty to, and do not intend to, update or revise the forward-looking statements in this discussion after the date hereof, except as may be required by law. In light of these risks and uncertainties, you should keep in mind that the events described in any forward-looking statement made in this discussion, or elsewhere, might not occur. View source version on businesswire.com : https://www.businesswire.com/news/home/20241210821417/en/ CONTACT: FOR INVESTOR INFORMATION CONTACT: William J. Skrobacz Investor Relations Phone: 804.788.5555 Fax: 804.788.5688 Email: investorrelations@newmarket.com KEYWORD: VIRGINIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CHEMICALS/PLASTICS ENERGY MANUFACTURING OIL/GAS SOURCE: NewMarket Corporation Copyright Business Wire 2024. PUB: 12/12/2024 05:01 PM/DISC: 12/12/2024 05:02 PM http://www.businesswire.com/news/home/20241210821417/en
( MENAFN - PR Newswire) Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PACS Group To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in PACS Group between (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's April 11, 2024 initial public offering ("IPO" or the "Offering"); and/or (b) all persons and entities that purchased or otherwise acquired PACS common stock pursuant, or traceable, or both, to the SPO Materials (as defined herein) issued in connection with PACS' September 2024 secondary public offering (the "SPO"); and/or (c) securities between April 11, 2024 and November 5, 2024 inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . [You may also click here for additional information] NEW YORK, Nov. 30, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against PACS Group, Inc. ("PACS Group" or the "Company") (NYSE: PACS ) and reminds investors of the January 13, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that the Company engaged in a "scheme" to submit false Medicare claims which "drove more than 100% of PACS' operating and net income from 2020 – 2023"; (2) that the Company engaged in a "scheme" to "bill thousands of unnecessary respiratory and sensory integration therapies to Medicare"; (3) that the Company engaged in a scheme to falsify documentation related to licensure and staffing; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On April 11, 2024, PACS Group conducted its IPO, selling 21,428,572 shares of common stock at a price of $21.00 per share, received net proceeds of approximately $450 million. On September 3, 2024, PACS filed with the SEC a registration statement for a secondary offering on Form S-1 (the "SPO Registration Statement"). On September 6, 2024, PACS filed with the SEC a prospectus for the SPO on Form 424B4, which formed part of the SPO Registration Statement (the "SPO Prospectus" and together with the SPO Registration Statement and attendant materials filed or published with these forms, the "SPO Materials." PACS issued 2,777,778 shares of common stock at $36.25 per share for proceeds of $100.7 million to the Company. Through the SPO, PACS insiders also sold 16,256,704 shares of common stock at $36.25 per share for proceeds of $589.3 million. On November 4, 2024, Hindenburg Research published a report based on a 5-month investigation that included interviews with 18 former PACS Group employees, competitors, and an analysis of more than 900 PACS facility cost reports. The report alleged the Company had "abused a COVID-era waiver" in a "scheme" that involved falsely submitting false Medicare claims which "drove more than 100% of PACS' operating and net income from 2020 – 2023, enabling PACS to IPO in early 2024 with the illusion of legitimate growth and profitability." The report further alleged the Company engaged in a scheme to maintain revenue by "bill[ing] thousands of unnecessary respiratory and sensory integration therapies to Medicare Part B regardless of clinical need or outcomes." The report also alleged a widespread practice of falsifying documentation, including by engaging in a "scheme whereby PACS attempts to fool regulators by 'renting' licenses from third parties to 'hang' on buildings" and then "either employs unlicensed administrators or has administrators manage multiple buildings in excess of state mandated limits." Similarly, the report alleges the Company engaged in a scheme related to licensure and staffing of nurses, whereby "PACS secretly lists uncertified nurse aides (NAs) as certified in the system, in an apparent scheme to cheat staffing ratios" and "retroactively add fake RN hours" in order "to meet minimum staffing requirements, boost star ratings, and avoid costly penalties." On this news, the Company's share price fell $11.93 or 27.78%, to close at $31.01 per share on November 4, 2024, on unusually heavy trading volume. Then, on November 6, 2024, before the market opened, the Company announced that it would postpone its fiscal third quarter 2024 earnings release. The Company further disclosed it had "received civil investigative demands from the federal government regarding the Company's reimbursement and referral practices that may or may not be related to this week's third-party report." On this news, the Company's share price fell $11.45 or 38.76%, to close at $18.09 per share on November 6, 2024, on unusually heavy trading volume. By the commencement of this action, PACS Group stock has traded as low as $18.09 per share, a more than 13.9% decline from the $21 per share IPO price. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding PACS Group's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the PACS Group class action, go to /PACS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . Follow us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLP MENAFN30112024003732001241ID1108941585 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.Renuka Rayasam | (TNS) KFF Health News In April, just 12 weeks into her pregnancy, Kathleen Clark was standing at the receptionist window of her OB-GYN’s office when she was asked to pay $960, the total the office estimated she would owe after she delivered. Clark, 39, was shocked that she was asked to pay that amount during this second prenatal visit. Normally, patients receive the bill after insurance has paid its part, and for pregnant women that’s usually only when the pregnancy ends. It would be months before the office filed the claim with her health insurer. Clark said she felt stuck. The Cleveland, Tennessee, obstetrics practice was affiliated with a birthing center where she wanted to deliver. Plus, she and her husband had been wanting to have a baby for a long time. And Clark was emotional, because just weeks earlier her mother had died. “You’re standing there at the window, and there’s people all around, and you’re trying to be really nice,” recalled Clark, through tears. “So, I paid it.” On online baby message boards and other social media forums , pregnant women say they are being asked by their providers to pay out-of-pocket fees earlier than expected. The practice is legal, but patient advocacy groups call it unethical. Medical providers argue that asking for payment up front ensures they get compensated for their services. How frequently this happens is hard to track because it is considered a private transaction between the provider and the patient. Therefore, the payments are not recorded in insurance claims data and are not studied by researchers. Patients, medical billing experts, and patient advocates say the billing practice causes unexpected anxiety at a time of already heightened stress and financial pressure. Estimates can sometimes be higher than what a patient might ultimately owe and force people to fight for refunds if they miscarry or the amount paid was higher than the final bill. Up-front payments also create hurdles for women who may want to switch providers if they are unhappy with their care. In some cases, they may cause women to forgo prenatal care altogether, especially in places where few other maternity care options exist. It’s “holding their treatment hostage,” said Caitlin Donovan, a senior director at the Patient Advocate Foundation . Medical billing and women’s health experts believe OB-GYN offices adopted the practice to manage the high cost of maternity care and the way it is billed for in the U.S. When a pregnancy ends, OB-GYNs typically file a single insurance claim for routine prenatal care, labor, delivery, and, often, postpartum care. That practice of bundling all maternity care into one billing code began three decades ago, said Lisa Satterfield, senior director of health and payment policy at the American College of Obstetricians and Gynecologists . But such bundled billing has become outdated, she said. Previously, pregnant patients had been subject to copayments for each prenatal visit, which might lead them to skip crucial appointments to save money. But the Affordable Care Act now requires all commercial insurers to fully cover certain prenatal services. Plus, it’s become more common for pregnant women to switch providers, or have different providers handle prenatal care, labor, and delivery — especially in rural areas where patient transfers are common. Some providers say prepayments allow them to spread out one-time payments over the course of the pregnancy to ensure that they are compensated for the care they do provide, even if they don’t ultimately deliver the baby. “You have people who, unfortunately, are not getting paid for the work that they do,” said Pamela Boatner, who works as a midwife in a Georgia hospital. While she believes women should receive pregnancy care regardless of their ability to pay, she also understands that some providers want to make sure their bill isn’t ignored after the baby is delivered. New parents might be overloaded with hospital bills and the costs of caring for a new child, and they may lack income if a parent isn’t working, Boatner said. In the U.S., having a baby can be expensive. People who obtain health insurance through large employers pay an average of nearly $3,000 out-of-pocket for pregnancy, childbirth, and postpartum care, according to the Peterson-KFF Health System Tracker . In addition, many people are opting for high-deductible health insurance plans, leaving them to shoulder a larger share of the costs. Of the 100 million U.S. people with health care debt, 12% attribute at least some of it to maternity care, according to a 2022 KFF poll . Families need time to save money for the high costs of pregnancy, childbirth, and child care, especially if they lack paid maternity leave, said Joy Burkhard , CEO of the Policy Center for Maternal Mental Health, a Los Angeles-based policy think tank. Asking them to prepay “is another gut punch,” she said. “What if you don’t have the money? Do you put it on credit cards and hope your credit card goes through?” Calculating the final costs of childbirth depends on multiple factors, such as the timing of the pregnancy , plan benefits, and health complications, said Erin Duffy , a health policy researcher at the University of Southern California’s Schaeffer Center for Health Policy and Economics. The final bill for the patient is unclear until a health plan decides how much of the claim it will cover, she said. But sometimes the option to wait for the insurer is taken away. During Jamie Daw’s first pregnancy in 2020, her OB-GYN accepted her refusal to pay in advance because Daw wanted to see the final bill. But in 2023, during her second pregnancy, a private midwifery practice in New York told her that since she had a high-deductible plan, it was mandatory to pay $2,000 spread out with monthly payments. Daw, a health policy researcher at Columbia University, delivered in September 2023 and got a refund check that November for $640 to cover the difference between the estimate and the final bill. “I study health insurance,” she said. “But, as most of us know, it’s so complicated when you’re really living it.” While the Affordable Care Act requires insurers to cover some prenatal services, it doesn’t prohibit providers from sending their final bill to patients early. It would be a challenge politically and practically for state and federal governments to attempt to regulate the timing of the payment request, said Sabrina Corlette , a co-director of the Center on Health Insurance Reforms at Georgetown University. Medical lobbying groups are powerful and contracts between insurers and medical providers are proprietary. Because of the legal gray area, Lacy Marshall , an insurance broker at Rapha Health and Life in Texas, advises clients to ask their insurer if they can refuse to prepay their deductible. Some insurance plans prohibit providers in their network from requiring payment up front. If the insurer says they can refuse to pay up front, Marshall said, she tells clients to get established with a practice before declining to pay, so that the provider can’t refuse treatment. Related Articles Your cool black kitchenware could be slowly poisoning you, study says. Here’s what to do Does fluoride cause cancer, IQ loss, and more? Fact-checking Robert F. Kennedy Jr.’s claims US towns plunge into debates about fluoride in water Older Americans living alone often rely on neighbors or others willing to help Nationwide IV fluid shortage could change how hospitals manage patient hydration Clark said she met her insurance deductible after paying for genetic testing, extra ultrasounds, and other services out of her health care flexible spending account. Then she called her OB-GYN’s office and asked for a refund. “I got my spine back,” said Clark, who had previously worked at a health insurer and a medical office. She got an initial check for about half the $960 she originally paid. In August, Clark was sent to the hospital after her blood pressure spiked. A high-risk pregnancy specialist — not her original OB-GYN practice — delivered her son, Peter, prematurely via emergency cesarean section at 30 weeks. It was only after she resolved most of the bills from the delivery that she received the rest of her refund from the other OB-GYN practice. This final check came in October, just days after Clark brought Peter home from the hospital, and after multiple calls to the office. She said it all added stress to an already stressful period. “Why am I having to pay the price as a patient?” she said. “I’m just trying to have a baby.” ©2024 KFF Health News. Distributed by Tribune Content Agency, LLC.
South Philly restaurant Bomb Bomb closes after more than 70 years in businessLight & Wonder, Inc. Announcement: If You Have Suffered Losses in Light & Wonder, Inc. ...
- Previous:
- Next: phlove casino login register app
